Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

Overview of attention for article published in OncoTargets and therapy, November 2016

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 1 X user

patent: 1 patent

Citations

dimensions_citation: 85 Dimensions

Readers on

mendeley: 73 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications

Grant US-10786438-B2

United States of America